13% of stroke cases are hemorrhagic strokes.
Hemorrhagic strokes happen when a blood vessel in the brain ruptures and bleeds into its surroundings. The blood then accumulates and compresses the surrounding tissues of the brain. There are two types of hemorrhagic strokes: intracerebral hemorrhage or subarachnoid hemorrhage.
Intracerebral hemorrhage occurs when the blood from the burst vessel leaks inside the brain. A subarachnoid hemorrhage is when the bleeding is in the area between the brain and the thin tissues that cover the brain.
There are two types of weakened blood vessels usually cause hemorrhagic stroke: aneurysms and arteriovenous malformations (AVMs). When a weakened area of a blood vessel starts to balloon, an aneurysm happens. If the aneurysm is left untreated, it will eventually rupture and bleed into the brain. An AVM on the other hand, is a group or cluster of abnormally formed blood vessels. These blood vessles can rupture and cause a hemorrhagic stroke.
Magnesium sulphate is believed to improve the outcome of an aneurysmal subarachnoid hemorrhage. It does so by reducing the occurrence or improving the outcome of delayed cerebral ischaemia. This type of treatment has been debated as to its usefulness and effectiveness.
Study should end debate over magnesium treatment for preventing poor outcome after hemorrhagic stroke
An international randomised trial and meta-analysis published Online First in The Lancet should put an end to the debate about the use of intravenous magnesium sulphate to prevent poor outcomes after hemorrhagic stroke. The investigators found no benefit from magnesium treatment compared with placebo.
"The findings from MASH 2 have important implications for clinical practice. Administration of magnesium is standard practice in many centres", explains Sanne Dorhout Mees* from University Medical Center Utrecht, Netherlands, who led the research.
Hemorrhagic strokes happen when a blood vessel in the brain ruptures and bleeds into its surroundings. The blood then accumulates and compresses the surrounding tissues of the brain. There are two types of hemorrhagic strokes: intracerebral hemorrhage or subarachnoid hemorrhage.
Intracerebral hemorrhage occurs when the blood from the burst vessel leaks inside the brain. A subarachnoid hemorrhage is when the bleeding is in the area between the brain and the thin tissues that cover the brain.
There are two types of weakened blood vessels usually cause hemorrhagic stroke: aneurysms and arteriovenous malformations (AVMs). When a weakened area of a blood vessel starts to balloon, an aneurysm happens. If the aneurysm is left untreated, it will eventually rupture and bleed into the brain. An AVM on the other hand, is a group or cluster of abnormally formed blood vessels. These blood vessles can rupture and cause a hemorrhagic stroke.
Magnesium sulphate is believed to improve the outcome of an aneurysmal subarachnoid hemorrhage. It does so by reducing the occurrence or improving the outcome of delayed cerebral ischaemia. This type of treatment has been debated as to its usefulness and effectiveness.
Study should end debate over magnesium treatment for preventing poor outcome after hemorrhagic stroke
An international randomised trial and meta-analysis published Online First in The Lancet should put an end to the debate about the use of intravenous magnesium sulphate to prevent poor outcomes after hemorrhagic stroke. The investigators found no benefit from magnesium treatment compared with placebo.
"The findings from MASH 2 have important implications for clinical practice. Administration of magnesium is standard practice in many centres", explains Sanne Dorhout Mees* from University Medical Center Utrecht, Netherlands, who led the research.